Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.
Harrison Widelitz
Advertisement
Articles by Harrison Widelitz
Daratumumab-based induction/consolidation and maintenance therapy resulted in durable MRD negativity in patients with newly diagnosed multiple myeloma.
Advertisement
Latest Updated Articles
Talquetamab-Based Triplet Elicits Deep Responses in R/R MyelomaSeptember 27th 2024
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
4
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
5